Bristol-Myers Squibb Company

BMYNYSEHealthcare● Active

$57.36

+$0.09(+0.16%)

Market Cap$117.1B

P/E Ratio—

52W High$62.89

52W Low$42.52

Avg Volume11.6M

Open$57.16

Beta0.24

Free Cash Flow Financials Revenue

Bristol-Myers Squibb Company (BMY) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

BMY · free cash flow · updated Jun 8, 2026

Core FCF metrics

BMY · FCF · TTM · margin & CAGR

Free cash flow was $12.85B for FY2025 (fiscal year ending 2025-12-31), down 7.9% year-over-year The FCF margin was 26.6%. Five-year CAGR stands at -0.7%.

FY2025 Free Cash Flow$12.85B▼ -7.9% YoY

Trailing 12M (TTM)$11.91Btrailing 4 quarters sum

FCF Margin26.6%$12.85B ÷ revenue

3-Year CAGR+2.4%FY2022 → FY2025

5-Year CAGR-0.7%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

BMY · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$14.16B(1.31B)$12.85B▼ 7.9%26.6%

FY2024$15.19B(1.25B)$13.94B▲ +10.2%28.9%

FY2023$13.86B(1.21B)$12.65B▲ +5.9%28.1%

FY2022$13.07B(1.12B)$11.95B▼ 21.6%25.9%

FY2021$16.21B(973M)$15.23B▲ +14.5%32.8%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

BMY · P/FCF · FCF yield · FCF per share

Bristol-Myers Squibb Company (BMY) trades at a FCF yield of 10.18% and a price-to-free-cash-flow ratio of 9.8x. FCF per share stands at $5.83, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

10.18%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$5.83

TTM FCF ÷ Shares Outstanding

Price / FCF

x9.8

Share Price ÷ FCF per Share

EV / FCF (TTM)

x12.8

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

BMY · cash flow statement · operating / investing / financing

For FY2025, Bristol-Myers Squibb Company generated $14.16B in operating cash flow and spent 1.31B in capital expenditures, yielding $12.85B in free cash flow.

Operating Activities

+$14.16B

Cash from core business operations

2025-12-31

Investing Activities

−$4.13B

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$10.35B

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($14.16B) − |CapEx| (1.31B) = FCF ($12.85B)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

BMY vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Bristol-Myers Squibb CompanyYOU

BMY

$12.85B-7.9%26.7%

65%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Bristol-Myers Squibb Company (BMY) reported free cash flow of $12.85B for FY2025 (fiscal year ending 2025-12-31), down 7.9% year-over-year. The FCF margin was 26.6%.

Based on available data, Bristol-Myers Squibb Company has maintained positive free cash flow for at least 15 fiscal year(s). FCF peaked at $15.23B in FY2021. The 5-year CAGR stands at -0.7%.

Bristol-Myers Squibb Company's FCF yield is 10.18% and price-to-FCF ratio is 9.8x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

BMY free cash flow · 8 questions

Bristol-Myers Squibb Company free cash flow was $12.85B for FY2025, down 7.9% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $11.91B.

BMY free cash flowBMY FCFBMY FCF 2025BMY free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Bristol-Myers Squibb Company · Bristol-Myers Squibb Company SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026